Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,382 across all filing types
Latest filing 2013-07-15 M&A Activity
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Communicated under the obligation to provide permanent information / Other communications
M&A Activity Classification · 99% confidence The document is a press release dated July 15, 2013, announcing the closing of Ipsen's acquisition of Syntaxin. It details the financial terms (€28 million upfront plus milestones) and strategic rationale (strengthening neurology R&D). Crucially, the document concludes by announcing details for a 'Media conference call' and a 'Webcast and Conference Call (in English) for financial analysts' regarding this announcement. This structure—a major corporate announcement followed immediately by details for an associated conference call—is characteristic of an Earnings Release (ER) or a significant corporate event announcement that is typically followed up by a call to discuss the details. Since this is an acquisition announcement, it is a major corporate event, but the presence of detailed conference call information strongly suggests it is intended to accompany or precede a discussion of results or major news. Given the content is a definitive announcement of a major transaction and includes call details, it aligns best with an Earnings Release (ER) if we consider major corporate news announcements that prompt analyst calls, or potentially a Regulatory Filing (RNS) if it were a mandatory filing. However, the format strongly resembles a press release detailing significant corporate news (an acquisition) and immediately scheduling a call to discuss it, which often falls under the umbrella of an ER or a general corporate update. Since it is not a quarterly financial report (IR) or a transcript (CT), and it is a detailed announcement rather than just a link (RPA), 'ER' is the closest fit for a major, time-sensitive corporate announcement that mandates an analyst call, even though the topic is M&A, not standard earnings. If M&A Activity (TAR) were an option for the primary announcement, that would be considered, but TAR is defined as 'Merger proposals or takeover bids.' This is the *closing* of an acquisition. Given the options, and the strong emphasis on the accompanying conference calls, it functions as a major corporate news release. I will classify it as an Earnings Release (ER) as it serves as the primary vehicle for disseminating significant corporate news requiring immediate analyst discussion, which is a common function of ERs even outside of standard quarterly reporting periods, or as a Regulatory Filing (RNS) as a general announcement. Given the detailed nature of the M&A announcement, I lean towards RNS as the most appropriate catch-all for significant, non-standard corporate actions that aren't explicitly covered by other codes like TAR (which implies proposal/bid, not closing). However, the presence of conference call details makes it function like an ER. I will select RNS as the most neutral fit for a major, non-standard corporate action announcement that isn't a standard financial report or a specific M&A proposal.
2013-07-15 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 88% confidence The document is a press release dated July 15, 2013, announcing a research collaboration between Ipsen and Harvard Medical School regarding recombinant botulinum toxins. It details the terms of the agreement, the objectives, and includes quotes from key personnel. This type of announcement, detailing a significant business development (a partnership/collaboration) that is not a standard periodic financial report (like 10-K or IR), nor a management change (MANG), nor a financing event (CAP), nor a transaction (POS/TAR), is best classified as a general corporate announcement. Since it is a specific, material business event announcement, it is not a generic Regulatory Filing (RNS) unless no other category fits. Given the options, this is a specific corporate action announcement. It is not an Earnings Release (ER) as it discusses R&D strategy, not financial results. It is not an Investor Presentation (IP). It is most closely aligned with a significant corporate development announcement. In the absence of a specific 'Corporate Development' code, and given that it is a detailed announcement of a strategic agreement, it does not fit well into the provided specific codes. However, if we must choose the closest fit among the provided options, it is a material announcement that doesn't fit the specific financial reporting or governance categories. Since it is a detailed announcement of a strategic R&D partnership, it is not a standard regulatory filing (RNS) but a specific corporate news item. Given the available codes, and recognizing this is a press release detailing a strategic R&D deal, it does not map perfectly. If we consider 'RNS' as the catch-all for material, non-standard announcements, it could fit there, but 'RPA' is for announcing the publication of *other* reports. Since this document itself is the primary announcement of the event, and it is not a financial report, the most appropriate fallback for a significant, non-standard corporate announcement that doesn't fit the other specific categories (like MANG, CAP, DIV, etc.) is RNS.
2013-07-15 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.